International Collaborative Ovarian Neoplasm studies (2): a trial of CAP versus carboplatin in advanced ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48215558

Enrollment

2000

Registered

2001-02-28

Start date

1991-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Ovarian cancer

Interventions

1. Cyclophosphamide, doxorubicin and cisplatin (CAP) 2. Single-agent carboplatin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Chemotherapy indicated 2. No previous malignancy 3. No prior radiotherapy or chemotherapy 4. No contraindication to chemotherapy

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Survival time 2. Progression-free survival	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026